JPS5826819A - Porous glass adsorbent for low-density lipoprotein particles - Google Patents

Porous glass adsorbent for low-density lipoprotein particles

Info

Publication number
JPS5826819A
JPS5826819A JP57043619A JP4361982A JPS5826819A JP S5826819 A JPS5826819 A JP S5826819A JP 57043619 A JP57043619 A JP 57043619A JP 4361982 A JP4361982 A JP 4361982A JP S5826819 A JPS5826819 A JP S5826819A
Authority
JP
Japan
Prior art keywords
porous glass
low
blood
average pore
pore diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57043619A
Other languages
Japanese (ja)
Other versions
JPS6362220B2 (en
Inventor
Masao Tanihara
正夫 谷原
Toshihide Nakajima
俊秀 中島
Koichi Takakura
高倉 孝一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuraray Co Ltd
Original Assignee
Kuraray Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuraray Co Ltd filed Critical Kuraray Co Ltd
Priority to JP57043619A priority Critical patent/JPS5826819A/en
Priority to CA000418834A priority patent/CA1189004A/en
Publication of JPS5826819A publication Critical patent/JPS5826819A/en
Publication of JPS6362220B2 publication Critical patent/JPS6362220B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

PURPOSE:To titled adsorbent that is made of a porous glass with a specific average pore size, thus permitting selective removal of low-density lipoprotein containing a large amount of cholesterols from the blood of a hypercholesterolemia patient. CONSTITUTION:The objective absorbent is made of a porous glass is which the average pore size ranges from 700 to 2,000Angstrom , preferably from 900 to 1,600Angstrom , the pore volume ranges from 0.3cc/g to 2.0cc/g and the particle size ranges from 0.1-5mm.. Further, when the average pore diameter is defined as D, the volume percentage of the pores with their diameter ranging from 0.8D to 1.2D is required to exceed 80 based on the total pore volume. In order to effect the selective adsorption of said protein, the pore size distribution of the porous glass is required to be narrow, the particle sizes preferably are in the above range in terms of the problem of hemolysis, since the particles are brought into contact with blood, plasma or other body liquids and the shape of the particles is preferably spherical in order to prevent the blood from coagulating.

Description

【発明の詳細な説明】 本発明は、高コレステロール血症患者血液中のコレステ
ロールを大量に含んだ低密度リボ蛋白質を除去できる吸
着剤に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an adsorbent capable of removing low density riboproteins containing a large amount of cholesterol from the blood of hypercholesterolemic patients.

高コレステロール血症、特に家族性高コレスデローμ血
症は遺伝的に細胞膜の低密度替ボ蛋白質すセデターの欠
損によシ、血中コレステロール濃度が高く、血管壁への
コレステロールの沈着により動脈硬化を引き起こし、さ
らには心筋梗塞や狭心症によシ死亡する率の高い疾患で
ある。そこでこれらの患者の血液中のコレステロールを
大量に含んだ低密度リボ蛋白質を除去する必要がある。
Hypercholesterolemia, especially familial hypercholesterolemia, is caused by a genetic defect in the cell membrane low-density cell membrane protein Sedator, resulting in high blood cholesterol levels and deposition of cholesterol on blood vessel walls, which can lead to arteriosclerosis. It is a disease with a high rate of death due to myocardial infarction and angina pectoris. Therefore, it is necessary to remove low-density riboproteins that contain large amounts of cholesterol from the blood of these patients.

従来、血漿交換法等が施行されていたが、毎回補充する
血漿が高価で品不足であるという問題点がある。
Conventionally, methods such as plasma exchange have been implemented, but there are problems in that the plasma that needs to be replenished each time is expensive and in short supply.

吸着法は、選択的にコレステロール、あるいは低密度リ
ボ蛋白質を除去できれば補液が要らないという長所があ
るが、このような吸着剤としてはヘハリンを固定化した
アガロース(8,Moorjaniら、  Cl1n、
 Chim、 Acts 77 (1977) 21−
30.)が使われ、効果があることが報告されているだ
けである。しかしながら担体であるアガロースが機械的
に弱く、又血液凝固因子をも同時に@着するという問題
点があった。また、血液中の老廃物や毒性物質を吸着除
去するために従来から使用されている活性炭や有機多孔
性樹脂あるいはイオン交換樹脂を用いたのでは、低密度
リボ蛋白質はほとんど吸着されない。
Adsorption methods have the advantage of not requiring fluid replacement if cholesterol or low-density riboproteins can be selectively removed, but such adsorbents include agarose immobilized with heharin (8, Moorjani et al., Cl1n,
Chim, Acts 77 (1977) 21-
30. ) have been used and reported to be effective. However, there was a problem that the carrier, agarose, was mechanically weak and blood coagulation factors were also attached at the same time. Moreover, when activated carbon, organic porous resin, or ion exchange resin, which has been conventionally used to adsorb and remove waste products and toxic substances in blood, is used, low density riboproteins are hardly adsorbed.

本発明者らはこれらの事情に鑑み鋭意研究を重ねた結果
、特定の平均細孔直径を持つ多孔性ガラスが血漿中の低
密度リボ蛋白質(したがってコレステロ−1%/)f:
選択的に減少させることを見出し、本発明を完成させる
に到った。即ち本発明は、平均細孔直径が700〜20
00人の範囲内にある多孔性ガラス(ただし表面にスル
ホン酸基を有さない)からなることを特徴とする低密度
リポ蛋白質吸着剤である。本発明の吸着剤が低密度リボ
蛋白質を選択的に吸着する理由は明らかではないが、多
孔性ガラスの表面に存在するシフノール基が蛋白質と何
らかの相互作用をする念めと推定される。
In view of these circumstances, the present inventors have conducted extensive research and have found that porous glass with a specific average pore diameter is able to absorb low-density riboproteins in plasma (therefore, cholesterol-1%/) f:
They have discovered that it can be selectively reduced and have completed the present invention. That is, in the present invention, the average pore diameter is 700 to 20
This is a low-density lipoprotein adsorbent characterized by being made of porous glass (but does not have sulfonic acid groups on the surface) within the range of 0.00 pores. The reason why the adsorbent of the present invention selectively adsorbs low-density riboproteins is not clear, but it is presumed that the Schifnol groups present on the surface of the porous glass have some kind of interaction with the protein.

低密度リボ蛋白質は分子量が数百刃の球状蛋白質である
ので、多孔性ガラスの平均細孔直径は700λ以上であ
ることが必要であり、900A以上であることが、さら
に好まし込。700Å以下の細孔には低密度リボ蛋白質
は吸着され難く、またγ−グロブリン等の池の蛋白質も
吸着されるので好ましくない。平均細孔直径が2000
Å以上になると物理的強度が低下して微細片を生じ易く
なるので好ましくない。平均細孔直径は1600Å以下
であることがさらに好ましい。
Since low-density riboprotein is a globular protein with a molecular weight of several hundred blades, the average pore diameter of the porous glass needs to be 700λ or more, and more preferably 900A or more. Low-density riboproteins are difficult to adsorb to pores of 700 Å or less, and pore proteins such as γ-globulin are also adsorbed therein, which is not preferable. Average pore diameter is 2000
If it exceeds Å, the physical strength decreases and fine pieces are likely to be formed, which is not preferable. More preferably, the average pore diameter is 1600 Å or less.

蛋白質を選択的に吸着するためには多孔性ガラスの細孔
径分布が狭いことが好ましく、平均細孔直径をDとする
とき、細孔直径が0.8D〜1.2Dの範囲内にある細
孔の容積の割合が全細孔容積の80饅以上を占めること
が好ましい。
In order to selectively adsorb proteins, it is preferable that the pore size distribution of the porous glass is narrow, and when the average pore diameter is D, the pore diameter is within the range of 0.8D to 1.2D. It is preferable that the volume of the pores accounts for 80 or more of the total pore volume.

また、多孔性ガラスの細孔容積は0.scc/Q〜2 
、0 QC/9の範囲内にあることが好ましい。0.5
cc、/f以下でI−i蛋白質の吸着容量が低く、本発
明の目的に適さなくなる。2 、0 cc79以上では
骨格が脆弱化して、微細破片が生じやすくなる。
In addition, the pore volume of porous glass is 0. scc/Q~2
, 0 QC/9. 0.5
Below cc, /f, the adsorption capacity of the I-i protein is low, making it unsuitable for the purpose of the present invention. If it exceeds 2.0 cc79, the skeleton becomes weak and fine fragments are likely to occur.

本発明において使用される多孔性ガラスは血液あるいは
血漿等の体液と接触させるため、粒子の直径が0.1M
II〜5mの範囲内にあることが好ましく、0.2aI
I〜2#の範囲にあることがさらに好ましい。粒径が0
.1mより小さくなると吸着体層の圧損が大きくなり、
溶血等の問題が生じる。粒径が5Mよシ大きいと粒子間
の空隙が大きくなり、吸着性能が低下し好ましくない。
Since the porous glass used in the present invention is brought into contact with body fluids such as blood or plasma, the diameter of the particles is 0.1M.
II to 5m, preferably within the range of 0.2aI
It is more preferably in the range of I to 2#. Particle size is 0
.. When it is smaller than 1 m, the pressure loss of the adsorbent layer becomes large.
Problems such as hemolysis occur. If the particle size is larger than 5M, the voids between the particles will become large, resulting in a decrease in adsorption performance, which is not preferable.

また本吸着剤は血液と接触させるため血球成分に対する
安全性を高め、また凝血等を防ぐため球状の外形のもの
が好ましい。
Further, since the present adsorbent is brought into contact with blood, it is preferable to have a spherical external shape in order to increase the safety against blood cell components and to prevent blood clots and the like.

多孔性ガラスはそのまま用いても良いが、血液との親和
性を向上させるために表面を親水性重合体で被覆処理し
て使用することもできる。親水性重合体の被覆方法とし
ては、多孔性ガラスを親水性重合体溶液に浸漬した後、
溶媒を除去する方法が好ましい。このような方法によれ
ば、親水性重合体は多孔性ガラスの細孔内にほとんど侵
入しないの中、細孔内表面に存在するシフノール基が親
水性重合体によシ被覆されて機能が低下することはほと
んどない。また、親水性重合体としては架橋成分を含む
重合体が好ましく、被覆処理後、加熱して架橋させるこ
とがさらに好ましい。親水性重合体の例としては、アク
リル酸エステル系重合体、メタクリル酸エステル系重合
体、アクリルアミド系重合体、ポリビニルアルコール系
重合体。
Porous glass may be used as it is, but its surface may be coated with a hydrophilic polymer to improve its affinity with blood. As a method of coating with a hydrophilic polymer, after immersing porous glass in a hydrophilic polymer solution,
A method that removes the solvent is preferred. According to this method, the hydrophilic polymer hardly penetrates into the pores of porous glass, but the Schifnol groups present on the inner surface of the pores are covered by the hydrophilic polymer, resulting in a decrease in functionality. There is little to do. Further, as the hydrophilic polymer, a polymer containing a crosslinking component is preferable, and it is more preferable to crosslink it by heating after the coating treatment. Examples of hydrophilic polymers include acrylic ester polymers, methacrylic ester polymers, acrylamide polymers, and polyvinyl alcohol polymers.

ポリビニルピロリドン、硝酸セルロース及びゼラチン等
をあげることができる。
Examples include polyvinylpyrrolidone, cellulose nitrate, and gelatin.

本発明の多孔性ガラスからなる低密度リポ蛋白質吸着剤
は通常カラムに充填して使用される。カラムは吸着剤層
の両側に血液回路と容易に接続し得る形状の入口部と出
口部を有する本体と、吸着剤層と出入口部との間に、血
液等は通過するが吸着剤は通過しない80〜180メツ
シユの網目を持つフィルターを備えているものが好まし
いが、池の形状であっても実質的に同様の機能を持つカ
フムであれば本目的に使用し得る。カラムの材質はガラ
ス、ポリエチレン、ポリプロピレン、ポリカーボネート
、ポリスチレン、ポリメチルメタクリレート等が使用で
きるがオートクレーブ滅菌が可能なポリプロピレンやポ
リカーボネート等が好ましい、フィルターは生理学的に
不活性で強度の高いものであれば良いが、特にポリエス
テル製のものが好ましい。
The low-density lipoprotein adsorbent made of porous glass of the present invention is usually used by filling a column. The column has a main body having an inlet and an outlet shaped to be easily connected to a blood circuit on both sides of an adsorbent layer, and a space between the adsorbent layer and the inlet and outlet, through which blood, etc. passes, but the adsorbent does not pass through. A filter having a mesh size of 80 to 180 meshes is preferred, but any cuff having substantially the same function can be used for this purpose even if it is shaped like a pond. The material of the column can be glass, polyethylene, polypropylene, polycarbonate, polystyrene, polymethyl methacrylate, etc., but polypropylene, polycarbonate, etc., which can be sterilized by autoclaving, are preferable.The filter should be physiologically inert and strong. However, those made of polyester are particularly preferred.

本発明の吸着剤は、水又は生理食塩水と共にカラムに充
填するのが好ましく、充填したカラムは通常滅菌して使
用されるが、オートクレーブ滅菌。
The adsorbent of the present invention is preferably packed into a column together with water or physiological saline, and the filled column is usually sterilized before use, but it can be sterilized by autoclaving.

r線滅菌が好ましい。R-ray sterilization is preferred.

本発明の吸着剤は、全血をそのまま接触させることもで
きるが、あらかじめ血漿分離装置等で分離した血漿だけ
を接触させても良い。
The adsorbent of the present invention can be brought into contact with whole blood as it is, but it may also be brought into contact with only plasma that has been separated in advance using a plasma separator or the like.

以下実施例によシ本発明をさらに具体的に説明するが、
本発明はかかる実施例に限定されるものではない。
The present invention will be explained in more detail with reference to Examples below.
The present invention is not limited to such embodiments.

実施例1〜2.比較例1 平均細孔直径が720人の多孔性ガラス(D=720人
、細孔直径が0.8D〜1.2Dにある細孔容積の割合
99囁、細孔容積0.95 cc、/g 、粒径0,2
a〜0.5M)を実施例1として使用し、平均細孔径が
1060人の多孔性ガラス(D、=1060人、細孔直
径が0.8D〜1.2Dにある細孔容積の割合81%。
Examples 1-2. Comparative Example 1 Porous glass with an average pore diameter of 720 (D = 720, the proportion of pore volume with a pore diameter of 0.8D to 1.2D is 99 sec, pore volume 0.95 cc, / g, particle size 0,2
a ~ 0.5M) as Example 1, a porous glass with an average pore diameter of 1060 people (D, = 1060 people, the proportion of the pore volume with a pore diameter of 0.8D ~ 1.2D 81 %.

細孔容積0.92 cc/f 、粒径0.211M〜0
5鱈)を実施例2として使用した。また、平均細孔直径
が560人の多孔性ガラス(D=560人、細孔直径が
0.8D〜1.2Dにある細孔容積の割合91%、細孔
容積0.76 cc/9 、粒径0.2W〜0.431
1)を比較例1として使用した。上記の多孔性ガフス各
2fをポリプロピレン製のカラム(両端に180メツシ
ユのポリエステル製のフィルター付)に充填シ、ウサギ
血漿20w1を37℃で5時間循環した。循環前後の総
蛋白質濃度をビウレット法で、コレステロール濃度tオ
μトー7りμアルデヒド法でそれぞれ定量し除去率を計
算した(除去率(%)=(1−循環後濃度/循環前濃度
)X100)。コレステロールは血液中に単独で存在す
ることはほとんど無く、大部分が低密度リボ蛋白質と結
合して存在している。従ってコレステロールの除去率と
低密度リボ蛋白質の除去率は実質上等しいと考えられる
ので、コレステロールの濃度を分析した。
Pore volume 0.92 cc/f, particle size 0.211M~0
5 cod) was used as Example 2. In addition, porous glass with an average pore diameter of 560 people (D = 560 people, 91% of the pore volume with a pore diameter of 0.8D to 1.2D, pore volume 0.76 cc/9, Particle size 0.2W~0.431
1) was used as Comparative Example 1. A polypropylene column (with a 180-mesh polyester filter on both ends) was filled with 2 f of each of the above-mentioned porous guffs, and 20 w1 of rabbit plasma was circulated at 37° C. for 5 hours. The total protein concentration before and after circulation was quantified by the biuret method and the cholesterol concentration was quantified by the aldehyde method, and the removal rate was calculated (removal rate (%) = (1 - concentration after circulation / concentration before circulation) x 100 ). Cholesterol rarely exists alone in the blood; most of it exists bound to low-density riboproteins. Therefore, since the removal rate of cholesterol and the removal rate of low-density riboprotein are considered to be substantially equal, the concentration of cholesterol was analyzed.

′jlIJ1表に示すように実施例の吸着剤による総蛋
白の減少は少なく、コレステロールFi50〜48%前
後が除去されるが、平均細孔直径が70OAより小さい
比較例1では、コレステロールの除去率は大きいが、総
蛋白質の除去率も大きくなシ選択性の低いものであった
As shown in Table 'jlIJ1, the decrease in total protein by the adsorbent of Example is small and about 50-48% of cholesterol Fi is removed, but in Comparative Example 1 where the average pore diameter is smaller than 70OA, the removal rate of cholesterol is Although it was large, the total protein removal rate was also large and the selectivity was low.

第  1  表 実施例5.比較例2〜5 実施例2で使用したのと同じ多孔性ガラスを実施例6と
して使用し、ローム・アンド・八−ス社の有機多孔性樹
脂であるXAD−4(D=280人。
Table 1 Example 5. Comparative Examples 2-5 The same porous glass used in Example 2 was used as Example 6, and the organic porous resin XAD-4 (D=280 people) from Rohm & Eighth.

細孔直径が0.8 D〜1.2Dにある細孔容積の割合
16%、細孔容積0.65 ca/9 、平均粒径0.
/iW)を・比較例2として使用し、XAD−y (D
=sbo人。
The proportion of the pore volume with a pore diameter of 0.8 D to 1.2 D is 16%, the pore volume is 0.65 ca/9, and the average particle size is 0.
/iW) was used as Comparative Example 2, and XAD-y (D
= sbo person.

細孔直径が0.8D〜1.2Dにある細孔容積の割合2
2哄、細孔容積0.66 cc/Q 、平均粒径o、a
m)414例3.!:L、XAD−8(D =36OA
、 +l1il孔1[径が0.8D〜1.2Dにある細
孔容積の割合22襲。
Proportion of pore volume with pore diameter between 0.8D and 1.2D2
2 volumes, pore volume 0.66 cc/Q, average particle size o, a
m) 414 cases 3. ! :L, XAD-8 (D = 36OA
, +l1il pore 1 [proportion of pore volume with diameter between 0.8D and 1.2D22].

細孔容積0.57 cc/f 、平均粒径0.8m!1
1)を比較例4として使用した。また、ダウ・ケミカル
社製のイオン交換樹脂Dowex I X 4 (CI
型)を比較例5として使用した。
Pore volume 0.57 cc/f, average particle size 0.8m! 1
1) was used as Comparative Example 4. In addition, the ion exchange resin Dowex I X 4 (CI
type) was used as Comparative Example 5.

上記の多孔体各19をポリプロピレン製のカラムに充填
し、人血漿10d’i37°Cで90分間循環し、前述
の方法で総蛋白質除去率とコレステロール除去率(すな
わち低密度リボ蛋白質除去率)を測定した。第2表に示
すように有機多孔性樹脂やイオン交換樹脂を用いたので
はコレステロールはほとんど除去されない。
Each of the above porous bodies 19 was packed in a polypropylene column, and human plasma was circulated at 10 d'i at 37°C for 90 minutes, and the total protein removal rate and cholesterol removal rate (i.e., low-density riboprotein removal rate) were determined by the method described above. It was measured. As shown in Table 2, cholesterol is hardly removed when organic porous resins or ion exchange resins are used.

以下余白Margin below

Claims (1)

【特許請求の範囲】 1、平均細孔直径が700人〜2000人の範囲内にあ
る多孔性ガラス(ただし表面にスルホン酸基を有さない
)からなることを特徴とする低密度リボ蛋白質吸着剤。 2、平均細孔直径が900A〜1600Aの範囲内にあ
る特許請求の範囲第1項記載の低密度リボ蛋白質吸着剤
。 5、多孔性ガラスの細孔容積がo、3cc7q以上、2
.000/f以下である特許請求の範囲第1項、第2項
のいずれかに記載の低密度リボ蛋白質吸着剤。 4、多孔性ガラスの粒子直径が0.1鱈〜5鱈の範囲内
にある特許請求の範囲第1項〜第3項のいずれかに記載
の低密度リポ蛋白質吸着剤。 5、多孔性ガラスが、平均細孔直径をDとするとき細孔
直径が0.8D〜1.2Dの範囲内にある細孔の容積の
割合が全細孔容積の8D哄以上を占める多孔性ガラスで
ある特許請求の範囲IJIc1項〜第4項のいずれかに
記載の低密度リポ蛋白質吸着剤。
[Scope of Claims] 1. Low-density riboprotein adsorption characterized by being made of porous glass (with no sulfonic acid groups on the surface) having an average pore diameter within the range of 700 to 2000 pores. agent. 2. The low-density riboprotein adsorbent according to claim 1, wherein the average pore diameter is within the range of 900A to 1600A. 5. The pore volume of the porous glass is o, 3cc7q or more, 2
.. 000/f or less, the low-density riboprotein adsorbent according to any one of claims 1 and 2. 4. The low-density lipoprotein adsorbent according to any one of claims 1 to 3, wherein the particle diameter of the porous glass is within the range of 0.1 to 5 dia. 5. The porous glass has pores in which the volume of pores with a pore diameter in the range of 0.8D to 1.2D accounts for 8D or more of the total pore volume, where D is the average pore diameter. The low-density lipoprotein adsorbent according to any one of Claims IJIc 1 to 4, which is a synthetic glass.
JP57043619A 1982-01-05 1982-03-17 Porous glass adsorbent for low-density lipoprotein particles Granted JPS5826819A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP57043619A JPS5826819A (en) 1982-03-17 1982-03-17 Porous glass adsorbent for low-density lipoprotein particles
CA000418834A CA1189004A (en) 1982-01-05 1983-01-04 Vessel with a handle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57043619A JPS5826819A (en) 1982-03-17 1982-03-17 Porous glass adsorbent for low-density lipoprotein particles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP56126443A Division JPS5827559A (en) 1981-08-11 1981-08-11 Low density lipoprotein adsorbent

Publications (2)

Publication Number Publication Date
JPS5826819A true JPS5826819A (en) 1983-02-17
JPS6362220B2 JPS6362220B2 (en) 1988-12-01

Family

ID=12668852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57043619A Granted JPS5826819A (en) 1982-01-05 1982-03-17 Porous glass adsorbent for low-density lipoprotein particles

Country Status (1)

Country Link
JP (1) JPS5826819A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582386B2 (en) 2001-03-06 2003-06-24 Baxter International Inc. Multi-purpose, automated blood and fluid processing systems and methods
US6884228B2 (en) 2001-03-06 2005-04-26 Baxter International Inc. Automated system adaptable for use with different fluid circuits
WO2009034949A1 (en) * 2007-09-12 2009-03-19 Rei Medical Co., Ltd. Adsorption column for purifying body fluid

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582386B2 (en) 2001-03-06 2003-06-24 Baxter International Inc. Multi-purpose, automated blood and fluid processing systems and methods
US6884228B2 (en) 2001-03-06 2005-04-26 Baxter International Inc. Automated system adaptable for use with different fluid circuits
WO2009034949A1 (en) * 2007-09-12 2009-03-19 Rei Medical Co., Ltd. Adsorption column for purifying body fluid
JP2009066117A (en) * 2007-09-12 2009-04-02 Rei Medical Co Ltd Adsorption column for body fluid purifying treatment

Also Published As

Publication number Publication date
JPS6362220B2 (en) 1988-12-01

Similar Documents

Publication Publication Date Title
US4472303A (en) Blood purification method
US11020521B2 (en) Hemocompatibility modifiers for cross-linked polymeric material
CN106457205B (en) Adsorption material for removing histone and biological source liquid purifying equipment
JP4578405B2 (en) Adsorbent and adsorber for low density lipoprotein and fibrinogen capable of whole blood treatment
GB2025385A (en) Activated carbon and apparatus for hemoperfusion
JPS5827559A (en) Low density lipoprotein adsorbent
JPS5826819A (en) Porous glass adsorbent for low-density lipoprotein particles
JP3633979B2 (en) Endotoxin adsorbent, adsorption removal method and adsorber
CA2232190C (en) Adsorbent for bradykinin, method for eliminating the same by adsorption, and adsorber
JPH0549694A (en) Adsorber of contrast medium
JP3272099B2 (en) Bradykinin adsorbent
JP2020006156A (en) Blood treatment beads
JP2534867B2 (en) Myoglobin adsorbent
JP2568846B2 (en) Myoglobin adsorbent
JPS63160669A (en) Low density lipoprotein adsorber
JPWO2002083202A1 (en) Body fluid treatment adsorber
JPH01124468A (en) Adsorbent of beta2-microglobulin
JPS62261367A (en) Adsorbent for beta 2 microglobulin
JPH0595999A (en) Adsorption body for contrast medium
JPH06296864A (en) Bradykinin adsorbent
JPS5838562A (en) Method and apparatus for regenerating protein adsorbent for body liquid treatment
JPH09220281A (en) Sterilizing method for body fluid treating device and sterilized body fluid treating device
NAKAJI et al. Therapeutic Plasmapheresis (XII), pp. 211-214 T. Agishi et al.(Eds)© VSP 1993
JP2568846C (en)
JPH0757238B2 (en) Adsorbent for β2 microglobulin for body fluid purification